Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C MutationFerdinandos Skoulidis, Ramaswamy Govindan, Bob T. Li et al.|New England Journal of Medicine|2021Cited by 1.8k
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic CancerJulien Dilly, Brian M. Wolpin, Andrew J. Aguirre et al.|Cancer Discovery|2024Cited by 234
Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.Georgina V. Long, F. Stephen Hodi, Reinhard Dummer et al.|Journal of Clinical Oncology|2016Cited by 110
Supplemental Table 1 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic CancerJulien Dilly, Brian M. Wolpin, Megan T. Hoffman et al.|Unknown|2024Cited by 0
Supplemental Table 7 from Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic CancerJulien Dilly, Brian M. Wolpin, Megan T. Hoffman et al.|Unknown|2024Cited by 0